Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATIC | P31939 | 9/20 | 0.51 |
| ▸ | GHSR | Q92847 | 3/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17801541 | 0.84 | ATIC (0.61) | ATICGHSRTHRB | |
| SCHEMBL17801575 | 0.84 | ATIC (0.61) | ATICGHSRTHRB | |
| SCHEMBL17801545 | 0.77 | ATIC (0.84) | ATICGHSRTHRB | |
| SCHEMBL17801547 | 0.77 | ATIC (0.84) | ATICGHSRTHRB | |
| SCHEMBL17808614 | 0.77 | ATIC (0.84) | ATICGHSRTHRB | |
| SCHEMBL17801500 | 0.69 | ATIC (0.54) | ATICGHSR | |
| SCHEMBL17801481 | 0.68 | ATIC (1.00) | ATICGHSRTHRB | |
| SCHEMBL17801569 | 0.68 | ATIC (1.00) | ATICGHSRTHRB | |
| SCHEMBL17801519 | 0.68 | ATIC (1.00) | ATICGHSRTHRB | |
| SCHEMBL17801493 | 0.68 | ATIC (0.74) | ATICGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3227279-A1 | 1 -OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS | Eli Lilly and Company (US) | 2017-10-11 | — | — | EP | disclosed |
| WO-2016089670-A1 | 1 -OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS | ELI LILLY AND COMPANY (US) | 2016-06-09 | — | — | WO | disclosed |